Yusaku Kajihara
Research Subjects
Research Interests
Yusaku Kajihara has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Ichiro Mizuki
Department of Gastroenterology Fuyoukai Murakami Hospital Aomori Japan
4 shared publicationsTadashi Shimoyama
Department of Gastroenterology, Hirosaki University Graduate School of Medicine, Japan
2 shared publicationsAkio Sannohe
Department of Orthopedics and Spine Surgery, Fuyoukai Murakami Hospital, Aomori, Japan
1 shared publication- Atsushi Kawaguchi
Second Department of Internal Medicine, National Defense Medical College
1 shared publication Jun Imai
Surgery, Tokorozawa Central Hospital
1 shared publication- Kazuhiro Matsuda
Graduate School of Engineering Kyoto University, Materials Sciences and Engineering, Yoshida-Honmachi, Sakyo-ku, Kyoto, Kyoto, 606-8501, Japan
1 shared publication
Latest Publications
- Open Access
- 4 April 2026
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 39 (3) , 199
Colonic anisakiasis incidentally detected during colonoscopy
Colonic anisakiasis incidentally detected during colonoscopy
- 4 April 2026
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 39 (3) , 199
Open AccessColonic anisakiasis incidentally detected during colonoscopy
Colonic anisakiasis incidentally detected during colonoscopy
- Open Access
- 1 April 2026
- Published by Modestum Ltd in Journal of Clinical and Experimental Investigations
- Vol. 17 (2) , em00855
An unusual cause of desquamative esophageal lesions
- 1 April 2026
- Published by Modestum Ltd in Journal of Clinical and Experimental Investigations
- Vol. 17 (2) , em00855
Open AccessAn unusual cause of desquamative esophageal lesions
- Open Access
- 27 January 2026
- Published by Modestum Ltd in Journal of Clinical and Experimental Investigations
- Vol. 17 (1) , em00853
Diverticulitis due to upper gastrointestinal series using barium
- 27 January 2026
- Published by Modestum Ltd in Journal of Clinical and Experimental Investigations
- Vol. 17 (1) , em00853
Open AccessDiverticulitis due to upper gastrointestinal series using barium
- Open Access
- 1 January 2026
- Published by XMLink in Chonnam Medical Journal
- Vol. 62 (2) , 97
An Unusual Cause of Abdominal Pain
Kajihara Y, et al. Chonnam Med J. 2026 May;62(2):97. https://doi.org/10.4068/cmj.2026.62.2.97
- 1 January 2026
- Published by XMLink in Chonnam Medical Journal
- Vol. 62 (2) , 97
Open AccessAn Unusual Cause of Abdominal Pain
Kajihara Y, et al. Chonnam Med J. 2026 May;62(2):97. https://doi.org/10.4068/cmj.2026.62.2.97
- Open Access
- 13 August 2025
- Published by Modestum Ltd in Journal of Clinical and Experimental Investigations
- Vol. 16 (3) , em00846
Megaesophagus due to achalasia
- 13 August 2025
- Published by Modestum Ltd in Journal of Clinical and Experimental Investigations
- Vol. 16 (3) , em00846
Open AccessMegaesophagus due to achalasia
- Open Access
- 25 April 2025
- Published by The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy in The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy
- Vol. 26 (1) , 55-58
Effective Combination Therapy with Nizatidine and Acotiamide for Functional Dyspepsia
Background: The two subgroups of Functional Dyspepsia (FD), including Postprandial Distress Syndrome (PDS) and Epigastric Pain Syndrome (EPS), can overlap. PDS–EPS overlap tends to reduce patients’ quality of life. Combination therapy with nizatidine and acotiamide may improve the symptoms of FD, including PDS–EPS overlap. A previous study reported the combined effect of rabeprazole and acotiamide. This study aimed to evaluate nizatidine as an alternative to rabeprazole.Methods: This single-center retrospective study analyzed 66 patients with FD, including 45 and 21 patients receiving nizatidine/acotiamide and rabeprazole/acotiamide therapies, respectively. The regimen comprised nizatidine 150 mg twice daily, rabeprazole 10 mg once daily, and acotiamide 100 mg thrice daily. No prokinetics other than acotiamide (e.g., rikkunshito and mosapride) were simultaneously administered. The following characteristics were investigated: age, sex, diabetes mellitus, Parkinson’s disease, mental illness, subgroups of FD (PDS, EPS, or PDS–EPS overlap), and treatment-emergent adverse events. Symptom improvement rates following treatment were calculated and compared.Results: Although differences in the FD subgroups were significant in terms of patients’ backgrounds, no significant difference in PDS–EPS overlap rates was observed (55.6% [25/45] vs. 61.9% [13/21], p = 0.79). The difference in symptom improvement rates between nizatidine/acotiamide and rabeprazole/acotiamide therapies was not significant (86.7% [39/45] vs. 85.7% [18/21], p = 1).Conclusion: Nizatidine/acotiamide therapy demonstrated efficacy comparable to rabeprazole/acotiamide therapy in treating FD. Patients with FD frequently experience treatment difficulties owing to various underlying factors; however, nizatidine/acotiamide therapy with a high symptom improvement rate is a promising therapeutic option in refractory FD.Keywords: Dyspepsia, nizatidine, rabeprazole
- 25 April 2025
- Published by The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy in The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy
- Vol. 26 (1) , 55-58
Open AccessEffective Combination Therapy with Nizatidine and Acotiamide for Functional Dyspepsia
Background: The two subgroups of Functional Dyspepsia (FD), including Postprandial Distress Syndrome (PDS) and Epigastric Pain Syndrome (EPS), can overlap. PDS–EPS overlap tends to reduce patients’ quality of life. Combination therapy with nizatidine and acotiamide may improve the symptoms of FD, including PDS–EPS overlap. A previous study reported the combined effect of rabeprazole and acotiamide. This study aimed to evaluate nizatidine as an alternative to rabeprazole.Methods: This single-center retrospective study analyzed 66 patients with FD, including 45 and 21 patients receiving nizatidine/acotiamide and rabeprazole/acotiamide therapies, respectively. The regimen comprised nizatidine 150 mg twice daily, rabeprazole 10 mg once daily, and acotiamide 100 mg thrice daily. No prokinetics other than acotiamide (e.g., rikkunshito and mosapride) were simultaneously administered. The following characteristics were investigated: age, sex, diabetes mellitus, Parkinson’s disease, mental illness, subgroups of FD (PDS, EPS, or PDS–EPS overlap), and treatment-emergent adverse events. Symptom improvement rates following treatment were calculated and compared.Results: Although differences in the FD subgroups were significant in terms of patients’ backgrounds, no significant difference in PDS–EPS overlap rates was observed (55.6% [25/45] vs. 61.9% [13/21], p = 0.79). The difference in symptom improvement rates between nizatidine/acotiamide and rabeprazole/acotiamide therapies was not significant (86.7% [39/45] vs. 85.7% [18/21], p = 1).Conclusion: Nizatidine/acotiamide therapy demonstrated efficacy comparable to rabeprazole/acotiamide therapy in treating FD. Patients with FD frequently experience treatment difficulties owing to various underlying factors; however, nizatidine/acotiamide therapy with a high symptom improvement rate is a promising therapeutic option in refractory FD.Keywords: Dyspepsia, nizatidine, rabeprazole
- Open Access
- 1 January 2025
- Published by XMLink in Chonnam Medical Journal
- Vol. 61 (2) , 94
Aortic Ring Sign: A Radiological Indicator of Anemia
Kajihara Y. Chonnam Med J. 2025 May;61(2):94-94. https://doi.org/10.4068/cmj.2025.61.2.94
- 1 January 2025
- Published by XMLink in Chonnam Medical Journal
- Vol. 61 (2) , 94
Open AccessAortic Ring Sign: A Radiological Indicator of Anemia
Kajihara Y. Chonnam Med J. 2025 May;61(2):94-94. https://doi.org/10.4068/cmj.2025.61.2.94
- Open Access
- 6 November 2024
- Published by Modestum Ltd in Journal of Clinical and Experimental Investigations
- Vol. 15 (4) , em00838
Trends in number of deaths due to alcohol-related liver diseases between 2017 and 2022 in Japan
- 6 November 2024
- Published by Modestum Ltd in Journal of Clinical and Experimental Investigations
- Vol. 15 (4) , em00838
Open AccessTrends in number of deaths due to alcohol-related liver diseases between 2017 and 2022 in Japan
- Open Access
- 10 October 2024
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 37 (3) , 168
Gastric volvulus: Bird’s beak sign on computed tomography
- 10 October 2024
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 37 (3) , 168
Open AccessGastric volvulus: Bird’s beak sign on computed tomography
- Open Access
- 26 August 2024
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 37 (2) , 114
Achalasia: Pinstripe pattern
- 26 August 2024
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 37 (2) , 114
Open AccessAchalasia: Pinstripe pattern